Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Shinkai
 
JapicCTI-205238
RCTfavipiravir placeboCOVID-19 mild to moderatesome concern
107/49 safety concern
  • inconclusive 40 % increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 18.5-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
2 studies excluded by filtering options (2 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).